Skip to content
MarketScale
‹ Back to IndustriesHealthcare

How AI Imaging Technology is Revolutionizing Orthopedics

Imaging and diagnostics are important facets in healthcare and nearly every area of medicine relies on this technology to diagnose or monitor conditions. In orthopedics, it is an especially vital tool, as it allows surgeons to discover and perform successful procedures for their patients. Currently, improved AI imaging technology is helping to support orthopedic surgeons…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from CurveBeam AI on MarketScale.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

Imaging and diagnostics are important facets in healthcare and nearly every area of medicine relies on this technology to diagnose or monitor conditions. In orthopedics, it is an especially vital tool, as it allows surgeons to discover and perform successful procedures for their patients. Currently, improved AI imaging technology is helping to support orthopedic surgeons in identifying and better detecting concerns and conditions. CurveBeam AI is a leader in developing equipment to assist orthopedic surgeons in this process and will help change the future of AI imaging technology and orthopedics.

In what way is AI imaging technology being used in orthopedics and how will it revolutionize surgical procedures?

To explore the topic in the “CurveBeam AI” podcast, Dr. Lew C. Schon, orthopedic surgeon and professor, interviewed Stuti Singh, the company’s Director of Imaging and Diagnostics. The two discussed the general expectations of imaging and diagnostics, AI imaging technology, and where AI stands to be a gamechanger in the imaging field.

Dr. Schon and Singh also talked more on the subject in regards to …

  1. The challenges pertaining to metal hardware and how it affects imaging but also assists CurveBeam AI in improving their technology
  2. How 2D images are converted to 3D images for higher quality and better orthopedic estimations
  3. How data and troubleshooting play a big factor in CurveBeam AI’s algorithm

“We will have customers send us examples of images they’re struggling with, of anatomy they want to see, but it’s too blurry… and we actually use those images that we get in our development. So, we will test newer versions of the algorithm with that clinical data, with their permission, of course. We actually even have some customers who have, in the validation of this product, to replace their multi-slice CT.

They have scanned a patient with metal hardware in multi-slice CT and in cone-beam CT and have shared the difference with us so we can see kind of what the more ideal image would look like on multi-slice CT and having that kind of ground truth is really useful as well. So, we work really closely with our customers and it’s really valuable, I think, going both ways because we are hopefully giving them the better and better product, but it’s really their feedback and their data that helps us get there,” said Singh.

Dr. Lew C. Schon is a board-certified orthopedic surgeon and is the Director of Orthopedic Innovation Institute of Foot and Ankle Reconstruction at Mercy Medical Center in Baltimore. He is also a professor of orthopedic surgery at NYU Langone and Johns Hopkins University, respectively.

Stuti Singh is the Director of Imaging and Diagnostics at CurveBeam AI. She has held that role for over a year now and has been with the company for more than eight years. Prior to that she worked as an engineer for Boeing. Singh is also an alum of Georgia Institute of Technology.

CurveBeam AI

Part of this channel

CurveBeam AI

AI-powered 3D bone analysis for orthopedic surgical planning.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus has made a $450 million deal with Alkeus to acquire two assets, including a phase 3 oral Stargardt program and a post-injection antiseptic. The focus now moves to clinical trial operations, chemistry manufacturing and controls, and plans for specialty distribution. These acquisitions aim to expand Tarsus' retina programs.

  • 01Tarsus acquired a phase 3 oral Stargardt asset and a post-injection antiseptic for $450 million.
  • 02The acquisitions focus on enhancing clinical trial operations and chemistry manufacturing controls.
  • 03Plans for future specialty distribution of the acquired assets are in place.

Aug 29, 2026

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

The FDA has released a generative AI discussion paper proposing a shift towards competency-style evaluation and increased postmarket monitoring in the healthcare industry. This move may lead vendors and hospital buyers to prioritize developing robust testing protocols for AI applications. The focus is on ensuring reliable and safe AI implementation in medical technologies.

  • 01The FDA's discussion paper suggests implementing competency-style evaluation for AI in healthcare.
  • 02There is an emphasis on increased postmarket monitoring for AI applications in the medical field.
  • 03Vendors and hospital buyers are encouraged to focus on developing testing protocols rather than presentations.

Aug 29, 2026

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 is focusing on integrating smart glasses and AI into the purchasing processes for optical retailers and labs. The event is anticipated to attract around 34,000 visitors and feature 950 exhibitors, indicating significant interest in AI imaging workflows and smart-glass innovations. The agenda highlights a future direction towards advanced technology in optical retail and laboratory settings.

  • 01SILMO Paris 2026 will host nearly 34,000 visitors and 950 exhibitors.
  • 02The event focuses on AI imaging workflows and smart-glass innovations for optical retailers and labs.
  • 03Significant interest is shown in integrating advanced technology within optical retail processes.

Aug 29, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512